Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Same-day versus next-day pegteograstim prophylaxis for chemotherapy-induced neutropenia
KCT0007694Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Nov 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegteograstim in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by GC Biopharma. Primary endpoint: Duration of grade 4 chemotherapy-induced neutropenia during cycle 1. Started Nov 2022; status: completed.
02
Drugs
pegteograstim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on KCT0007694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007694.